BioSpace News Archive

Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced financial results for the third quarter ended September 30, 2020 and reviewed recent corporate achievements and updates.

Cidara Therapeutics, Inc., a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, reported financial results for the three months ended September 30, 2020, and provided an update on its corporate activities.

Boehringer Ingelheim announced results from an interim analysis of the SENSCIS®-ON trial evaluating Ofev® in patients with systemic sclerosis-associated interstitial lung disease.

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced interim results from the ongoing SUMMIT trial of neratinib in the cohort of metastatic non-small cell lung cancer (NSCLC) patients with epidermal growth factor (EGFR) exon 18 mutations that has been previously treated with an EGFR targeted tyrosine kinase inhibitor (TKI).

Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T-cell immunotherapy, announced that President & CEO Usman “Oz” Azam will present at two upcoming virtual investor conferences in November.

Flexion Therapeutics, Inc. announced that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 29th Annual Credit Suisse Virtual Healthcare Conference.

ERYTECH Pharma,a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, provided a business and financial update.

Surgalign Holdings, Inc. announced that it is changing its earnings release and conference call date for the third quarter 2020 as a result of a delay completing the financial statements due to the additional workload created by the recently completed sale of the OEM business and its classification as discontinued operations.

Eiger BioPharmaceuticals, Inc., focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, reported financial results for third quarter 2020 and provided a business update.

Top-line Results from 52-week Phase 3 Study with Valoctocogene Roxaparvovec for Severe Hemophilia A Expected Early 2021